Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a.Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.
